UK markets open in 4 hours 54 minutes
  • NIKKEI 225

    28,740.18
    -778.16 (-2.64%)
     
  • HANG SENG

    27,980.56
    -615.10 (-2.15%)
     
  • CRUDE OIL

    64.60
    -0.32 (-0.49%)
     
  • GOLD FUTURES

    1,837.40
    -0.20 (-0.01%)
     
  • DOW

    34,742.82
    -34.94 (-0.10%)
     
  • BTC-GBP

    39,182.98
    -2,724.33 (-6.50%)
     
  • CMC Crypto 200

    1,454.90
    -106.40 (-6.81%)
     
  • ^IXIC

    13,401.86
    -350.38 (-2.55%)
     
  • ^FTAS

    4,060.80
    -5.38 (-0.13%)
     

LIDDS Annual Report 2020

  • Oops!
    Something went wrong.
    Please try again later.
LIDDS AB
·1-min read
  • Oops!
    Something went wrong.
    Please try again later.

UPPSALA, SWEDEN – LIDDS publishes Annual Report for 2020

The Annual Report is attached to this press release and alos available on LIDDS website: https://liddspharma.com/investors/#financial-reports.

For more information, please contact:
Monica Wallter, CEO, LIDDS +46 (0)737 07 09 22 monica.wallter@liddspharma.com

LIDDS AB is required to disclose this information pursuant to Nasdaq First North Growth Market – Rulebook. The information was submitted for publication, through the agency of the aforementioned contact person, on April 16, 2021 at 15:00 CET.

LIDDS AB (publ) is a Swedish-based pharmaceutical company with a unique drug delivery technology NanoZolid®. NanoZolid® is a clinically validated drug development technology and superior in its ability to provide a controlled and sustained release of active drug substances for up to six months. LIDDS has licensing agreements where NanoZolid is combined with antiandrogens and in-house development projects in clinical and preclinical phase for cytostatics and immunoactive agents. LIDDS (LIDDS) shares are listed on Nasdaq First North Growth Market. Redeye AB, certifiedadviser@redeye.se, +46 (0)8 121 576 90, is a certified adviser to LIDDS. For more information, please visit www.liddspharma.com.

Attachment